Polaris Group
TWSE:6550

Watchlist Manager
Polaris Group Logo
Polaris Group
TWSE:6550
Watchlist
Price: 46.05 TWD -0.97% Market Closed
Market Cap: 35.5B TWD
Have any thoughts about
Polaris Group?
Write Note

Net Margin
Polaris Group

-4 826.4%
Current
-18 477%
Average
-7.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 826.4%
=
Net Income
-1.7B
/
Revenue
35.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
KY
Polaris Group
TWSE:6550
34.3B TWD
-4 826%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.6B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
136.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
Country KY
Market Cap 34.3B TWD
Net Margin
-4 826%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.6B USD
Net Margin
9%
Country US
Market Cap 141.2B USD
Net Margin
13%
Country US
Market Cap 117.3B USD
Net Margin
0%
Country US
Market Cap 105.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 136.4B AUD
Net Margin
18%
Country US
Market Cap 78.4B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Polaris Group
Glance View

Market Cap
34.3B TWD
Industry
Biotechnology

In the competitive realm of biotechnology, Polaris Group has carved out a niche by focusing on the research and development of novel cancer therapeutics. Founded with a mission to bring innovative treatments to patients with unmet medical needs, the company has strategically positioned itself within the oncology sector. Polaris Group's approach is to harness the power of immunotherapy, aiming to develop solutions that enhance the immune system's ability to target and destroy cancer cells. This ambitious pursuit leverages cutting-edge technologies and a robust pipeline of investigational drugs, with particular emphasis on engineered drug compounds that can target specific pathways essential for cancer cell survival and proliferation. The key to Polaris Group's financial ecosystem is its revenue generation through strategic partnerships and collaborations with major pharmaceutical companies. By partnering with larger firms, Polaris is able to co-develop its breakthrough therapies, thus sharing the burden of development costs and risks. This model not only facilitates the advancement of their drug candidates but also offers potential revenue streams from milestone payments and royalties upon successful commercialization. Polaris’s business model underscores the significance of collaboration in biotech, where innovative ideas need both scientific expertise and considerable financial backing to transform into viable market solutions, ultimately contributing to the company's profitability and sustained growth in the competitive pharmaceutical landscape.

Intrinsic Value
2.99 TWD
Overvaluation 94%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 826.4%
=
Net Income
-1.7B
/
Revenue
35.1m
What is the Net Margin of Polaris Group?

Based on Polaris Group's most recent financial statements, the company has Net Margin of -4 826.4%.